H1抗组胺药对2型糖尿病患者肝细胞癌风险的影响。
Effects of H1-Antihistamines on hepatocellular carcinoma risk in patients with type 2 diabetes mellitus.
作者信息
Wu Szu-Yuan, Chen Wan-Ming, Chen Yi-Chan, Chiang Ming-Feng, Lee Ming-Che, Soong Ruey-Shyang
机构信息
1Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University, New Taipei City, Taiwan; Artificial Intelligence Development Center, Fu Jen Catholic University, New Taipei City, Taiwan; Department of Food Nutrition and Health Biotechnology, College of Medical and Health Science, Asia University, Taichung, Taiwan; Big Data Center, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan; Division of Radiation Oncology, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan; Department of Healthcare Administration, College of Medical and Health Science, Asia University, Taichung, Taiwan; Centers for Regional Anesthesia and Pain Medicine, Taipei Municipal Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
1Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University, New Taipei City, Taiwan; Artificial Intelligence Development Center, Fu Jen Catholic University, New Taipei City, Taiwan.
出版信息
Diabetes Metab. 2023 Jan;49(1):101393. doi: 10.1016/j.diabet.2022.101393. Epub 2022 Sep 25.
PURPOSE
H1-antihistamines (AHs) may exert protective effects against cancer. We investigated the association of AH use with hepatocellular carcinoma (HCC) risk in type 2 diabetes mellitus (T2DM) patients without hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
METHODS
The data of patients with T2DM enrolled from Taiwan's National Health Insurance Research Database were examined for the period of January 1, 2008, to December 31, 2018. We used the Kaplan-Meier method and Cox proportional hazards regression to evaluate the AH use-HCC risk association.
RESULTS
After 1:1 propensity score matching was performed, the two cohorts were each divided into AH users (n = 47,990) and nonusers (n = 47,990). The risk of HCC was significantly lower in AH users than in AH nonusers (adjusted hazard ratio [aHR]: 0.55 95% confidence interval [95% CI], 0.46 to 0.67; IRR: 0.70; 95% CI, 0.60 to 0.84), respectively. The dose-response relationship between AH use and HCC risk was also observed (aHRs: 0.58, 0.56, 0.50, and 0.41 for 28-35, 36-49, 50-77, and >77 cumulative defined daily doses of AH, respectively).
CONCLUSION
AH use can reduce HCC risk in T2DM patients without HBV or HCV infection in a dose-dependent manner.
目的
H1抗组胺药（AHs）可能对癌症具有保护作用。我们研究了在未感染乙型肝炎病毒（HBV）或丙型肝炎病毒（HCV）的2型糖尿病（T2DM）患者中，使用AHs与肝细胞癌（HCC）风险之间的关联。
方法
对2008年1月1日至2018年12月31日期间从台湾国民健康保险研究数据库中纳入的T2DM患者数据进行检查。我们使用Kaplan-Meier方法和Cox比例风险回归来评估使用AHs与HCC风险之间的关联。
结果
在进行1:1倾向评分匹配后，两个队列各自分为AH使用者（n = 47,990）和非使用者（n = 47,990）。AH使用者的HCC风险显著低于非使用者（调整后风险比[aHR]：0.55；95%置信区间[95%CI]，0.46至0.67；发病率比值比[IRR]：0.70；95%CI，0.60至0.84）。还观察到了AH使用与HCC风险之间的剂量反应关系（对于AH的累积限定日剂量分别为28 - 35、36 - 49、50 - 77和>77时，aHR分别为0.58、0.56、0.50和0.41）。
结论
在未感染HBV或HCV的T2DM患者中，使用AHs可呈剂量依赖性降低HCC风险。
Zotero 插件